380 related articles for article (PubMed ID: 26573597)
1. The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer.
Gevensleben H; Dietrich D; Golletz C; Steiner S; Jung M; Thiesler T; Majores M; Stein J; Uhl B; Müller S; Ellinger J; Stephan C; Jung K; Brossart P; Kristiansen G
Clin Cancer Res; 2016 Apr; 22(8):1969-77. PubMed ID: 26573597
[TBL] [Abstract][Full Text] [Related]
2. The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort.
Ness N; Andersen S; Khanehkenari MR; Nordbakken CV; Valkov A; Paulsen EE; Nordby Y; Bremnes RM; Donnem T; Busund LT; Richardsen E
Oncotarget; 2017 Apr; 8(16):26789-26801. PubMed ID: 28460462
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy.
Gevensleben H; Holmes EE; Goltz D; Dietrich J; Sailer V; Ellinger J; Dietrich D; Kristiansen G
Oncotarget; 2016 Nov; 7(48):79943-79955. PubMed ID: 27835597
[TBL] [Abstract][Full Text] [Related]
4. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
Cooper WA; Tran T; Vilain RE; Madore J; Selinger CI; Kohonen-Corish M; Yip P; Yu B; O'Toole SA; McCaughan BC; Yearley JH; Horvath LG; Kao S; Boyer M; Scolyer RA
Lung Cancer; 2015 Aug; 89(2):181-8. PubMed ID: 26024796
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.
Vassilakopoulou M; Avgeris M; Velcheti V; Kotoula V; Rampias T; Chatzopoulos K; Perisanidis C; Kontos CK; Giotakis AI; Scorilas A; Rimm D; Sasaki C; Fountzilas G; Psyrri A
Clin Cancer Res; 2016 Feb; 22(3):704-13. PubMed ID: 26408403
[TBL] [Abstract][Full Text] [Related]
7. CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients.
Goltz D; Holmes EE; Gevensleben H; Sailer V; Dietrich J; Jung M; Röhler M; Meller S; Ellinger J; Kristiansen G; Dietrich D
Oncotarget; 2016 Aug; 7(33):53309-53320. PubMed ID: 27462860
[TBL] [Abstract][Full Text] [Related]
8. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
[TBL] [Abstract][Full Text] [Related]
9. Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide.
Calagua C; Russo J; Sun Y; Schaefer R; Lis R; Zhang Z; Mahoney K; Bubley GJ; Loda M; Taplin ME; Balk SP; Ye H
Clin Cancer Res; 2017 Nov; 23(22):6812-6822. PubMed ID: 28893901
[No Abstract] [Full Text] [Related]
10. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.
Harter PN; Bernatz S; Scholz A; Zeiner PS; Zinke J; Kiyose M; Blasel S; Beschorner R; Senft C; Bender B; Ronellenfitsch MW; Wikman H; Glatzel M; Meinhardt M; Juratli TA; Steinbach JP; Plate KH; Wischhusen J; Weide B; Mittelbronn M
Oncotarget; 2015 Dec; 6(38):40836-49. PubMed ID: 26517811
[TBL] [Abstract][Full Text] [Related]
11. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
[TBL] [Abstract][Full Text] [Related]
13. Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas.
Mukaigawa T; Hayashi R; Hashimoto K; Ugumori T; Hato N; Fujii S
J Surg Oncol; 2016 Jul; 114(1):36-43. PubMed ID: 27111278
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy.
Chang YL; Yang CY; Lin MW; Wu CT; Yang PC
Lung Cancer; 2015 Jun; 88(3):254-9. PubMed ID: 25862146
[TBL] [Abstract][Full Text] [Related]
15. Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer.
Ishii H; Azuma K; Kawahara A; Yamada K; Imamura Y; Tokito T; Kinoshita T; Kage M; Hoshino T
J Thorac Oncol; 2015 Mar; 10(3):426-30. PubMed ID: 25384063
[TBL] [Abstract][Full Text] [Related]
16. Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas.
Zeng J; Zhang XK; Chen HD; Zhong ZH; Wu QL; Lin SX
Oncotarget; 2016 Feb; 7(8):8944-55. PubMed ID: 26771840
[TBL] [Abstract][Full Text] [Related]
17. Diffuse high intensity PD-L1 staining in thymic epithelial tumors.
Padda SK; Riess JW; Schwartz EJ; Tian L; Kohrt HE; Neal JW; West RB; Wakelee HA
J Thorac Oncol; 2015 Mar; 10(3):500-8. PubMed ID: 25402569
[TBL] [Abstract][Full Text] [Related]
18. Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma.
Callea M; Albiges L; Gupta M; Cheng SC; Genega EM; Fay AP; Song J; Carvo I; Bhatt RS; Atkins MB; Hodi FS; Choueiri TK; McDermott DF; Freeman GJ; Signoretti S
Cancer Immunol Res; 2015 Oct; 3(10):1158-64. PubMed ID: 26014095
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status.
Shin SJ; Jeon YK; Kim PJ; Cho YM; Koh J; Chung DH; Go H
Ann Surg Oncol; 2016 Feb; 23(2):694-702. PubMed ID: 26464193
[TBL] [Abstract][Full Text] [Related]
20. Programmed Death-Ligand 1 Expression in Muscle-Invasive Bladder Cancer Cystectomy Specimens and Lymph Node Metastasis: A Reliable Treatment Selection Biomarker?
Mukherji D; Jabbour MN; Saroufim M; Temraz S; Nasr R; Charafeddine M; Assi R; Shamseddine A; Tawil AN
Clin Genitourin Cancer; 2016 Apr; 14(2):183-7. PubMed ID: 26775720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
